NJ-LABVANTAGE-SOLUTIONS
25.3.2021 12:32:05 CET | Business Wire | Press release
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the appointment of Mikael Hagstroem as Chief Executive Officer. Mr. Hagstroem brings LabVantage almost 30 years of experience as a pioneer and expert in digital transformation, helping global enterprises harness data and analytics to reimagine their business models, achieve better performance, and create a long-term sustainable advantage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210325005048/en/
In his 25 years at the SAS Institute, Mr. Hagstroem helped build the analytics software powerhouse into a multibillion-dollar enterprise that is one of the world’s largest privately held software businesses. His client focus and success in consistently growing sales and profits resulted in assignments of increasing responsibility. He ultimately held the positions of Executive Vice President of SAS and President of SAS International, with P&L responsibility for more than half of total corporate revenues.
Mr. Hagstroem then became a Partner at McKinsey & Company and Chief Operating Officer of McKinsey Analytics, which helps companies create and scale new delivery models for analytics and artificial intelligence (AI). Most recently he was CEO and President at MetricStream, the world’s largest independent provider of governance, risk, and compliance products and solutions, where he led its transformation to a software as a service (SaaS) model, launched its Integrated Risk Management Platform, and championed integration of AI features into the platform.
A respected strategist and opinion leader in the fields of analytics, digital transformation and AI, Mr. Hagstroem is currently on the Board of Advisors of the AI Forum and has served as Chair of the World Economic Forum’s Global Agenda Council on Data-Driven Development, as a member of the Executive Committee of the U.S. Council for International Business, and as an Executive Board member of the Atlantic Council. He is also an Independent Director of Planet Smart City, which integrates architectural, digital, and environmental solutions to deliver high-quality low-cost housing.
“Mikael embodies the sense of purpose and passion required to tackle big goals and the expertise to achieve them,” said Dr. Purnendu Chatterjee, Chairman of LabVantage Solutions. “He is an accomplished business leader who has built innovative data-based enterprises across a range of industries. He is a visionary strategist who understands the transformational potential of advanced technologies and translates them into actionable business initiatives. An inspired leader, Mikael is committed to accelerating the use of new tools such as analytics and AI to address urgent global problems. We are thrilled to welcome him to LabVantage and excited at the prospect of what we can accomplish together.”
“LabVantage brings the Fourth Industrial Revolution−characterized as a range of new technologies that are fusing the physical, digital and biological worlds and impacting all disciplines, economies and industries−to the lab, and I am honored to take the helm,” said Mr. Hagstroem. “LabVantage is on the forefront of innovation, incorporating advanced technologies in easy-to-use solutions that are making the digital transformation of the laboratory a reality. The company has tremendous opportunities working at the intersection of the biological and digital revolutions, allowing us to help customers solve ever more complex problems and achieve disruptive growth. I look forward to working with the talented LabVantage team at this unique time when our future has never been brighter.”
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005048/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
